Glucosum Et Natrium Chloratum 1:1 Fresenius

Glucosum Et Natrium Chloratum 1:1 Fresenius is an intravenous injection solution that combines sodium chloride and glucose monohydrate in a 1:1 ratio. The product is supplied as a sterile solution for infusion, intended for fluid and electrolyte replenishment. It is marketed in the European Union and requires a prescription. The exact concentration of each component is not disclosed in the label.

Glucosum Et Natrium Chloratum 1:1 Fresenius is used in clinical settings to restore fluid balance and provide an energy source when oral intake is insufficient.

- Replacement of extracellular fluid losses due to surgery, trauma, or burns. - Correction of hyponatremia or other electrolyte disturbances. - Support of parenteral nutrition regimens by supplying glucose. - Maintenance of intravascular volume during diagnostic or therapeutic procedures. - Adjunctive therapy in patients receiving other intravenous medications that may cause electrolyte shifts.

Adverse reactions to Glucosum Et Natrium Chloratum 1:1 Fresenius are generally related to the infusion itself or the individual components.

Common: - Mild infusion site irritation or erythema. - Transient hyperglycemia, especially in patients with impaired glucose tolerance. - Slight increase in serum sodium levels. - Fluid overload manifested as peripheral edema.

Serious: - Severe hypernatremia leading to neurologic symptoms. - Anaphylactoid reactions such as urticaria, bronchospasm, or hypotension. - Metabolic acidosis in patients with compromised renal function. - Pulmonary edema due to excessive volume administration.

When prescribing or administering Glucosum Et Natrium Chloratum 1:1 Fresenius, clinicians should observe several safety considerations.

- Verify patient’s electrolyte status and serum glucose before infusion. - Adjust infusion rate in patients with heart failure or renal insufficiency to avoid fluid overload. - Use aseptic technique to prevent contamination of the sterile solution. - Monitor vital signs and laboratory values during and after administration. - Avoid rapid bolus administration unless specifically indicated. - Consider alternative formulations for patients with known hypersensitivity to sodium chloride or glucose.

Glucosum Et Natrium Chloratum 1:1 Fresenius may interact with other intravenous agents or systemic medications.

Avoid: - Concurrent high‑dose insulin therapy without glucose monitoring, which can precipitate hypoglycemia. - Large volumes of other sodium‑containing solutions that may cause hypernatremia. - Medications that increase the risk of fluid overload, such as certain chemotherapeutic agents.

Use with caution: - Diuretics, which may alter electrolyte balance and require closer monitoring. - Corticosteroids, which can affect glucose metabolism. - Vasopressors, as changes in intravascular volume may influence hemodynamic response. - Renal replacement therapies, where electrolyte shifts are common.